Baseline characteristics among California cancer patients with 13 common cancers by CAT, 2005-2017
| . | All . | CAT . | No CAT . | P value . | |||
|---|---|---|---|---|---|---|---|
| Characteristics . | n (%) . | n (%) . | n (%) . | ||||
| All | 942 109 (100.0) | 62 003 (100.0) | 880 106 (100.0) | ||||
| Gender | |||||||
| Male | 443 089 (47.0) | 29 589 (47.7) | 413 500 (47.0) | 0.0003 | |||
| Female | 498 898 (53.0) | 32 402 (52.3) | 466 496 (53.0) | ||||
| Race/Ethnicity | |||||||
| Non-Hispanic White | 573 453 (60.9) | 39 135 (63.1) | 534 318 (60.7) | <.0001 | |||
| African American | 68 336 (7.3) | 6585 (10.6) | 61 751 (7.0) | ||||
| Hispanic | 175 521 (18.6) | 10 780 (17.4) | 164 741 (18.7) | ||||
| Asian/Pacific Islander | 110 895 (11.8) | 4931 (8.0) | 105 964 (12.0) | ||||
| Other/Unknown | 13 904 (1.5) | 572 (0.9) | 13 332 (1.5) | ||||
| Median age at cancer diagnosis (q1, q3) | 65 (56, 75) | 66 (57, 75) | 65 (56, 75) | <.0001 | |||
| Cancer site | |||||||
| Breast | 209 444 (22.2) | 7642 (12.3) | 201 802 (22.9) | <.0001 | |||
| Prostate | 180 807 (19.2) | 7271 (11.7) | 173 536 (19.7) | ||||
| Lung | 135 075 (14.3) | 12 442 (20.1) | 122 633 (13.9) | ||||
| Colorectal | 121 874 (12.9) | 8321 (13.4) | 113 553 (12.9) | ||||
| NHL | 56 771 (6.0) | 3951 (6.4) | 52 820 (6.0) | ||||
| Bladder | 24 964 (2.6) | 2295 (3.7) | 22 669 (2.6) | ||||
| Uterine | 47 295 (5.0) | 3560 (5.7) | 43 735 (5.0) | ||||
| Kidney | 44 345 (4.7) | 2781 (4.5) | 41 564 (4.7) | ||||
| Pancreatic | 36 679 (3.9) | 4604 (7.4) | 32 075 (3.6) | ||||
| Stomach | 24 689 (2.6) | 2162 (3.5) | 22 527 (2.6) | ||||
| Ovarian | 22 528 (2.4) | 2876 (4.6) | 19 652 (2.2) | ||||
| Brain | 19 039 (2.0) | 2249 (3.6) | 16 790 (1.9) | ||||
| Myeloma | 18 599 (2.0) | 1849 (3.0) | 16 750 (1.9) | ||||
| Year of cancer diagnosis | |||||||
| 2005-2007 | 230 451 (24.5) | 16 161 (26.1) | 214 290 (24.3) | <.0001 | |||
| 2008-2010 | 234 624 (24.9) | 16 232 (26.2) | 218 392 (24.8) | ||||
| 2011-2013 | 216 707 (23.0) | 14 301 (23.1) | 202 406 (23.0) | ||||
| 2014-2017 | 260 327 (27.6) | 15 309 (24.7) | 245 018 (27.8) | ||||
| Stage at diagnosis | |||||||
| Stage I | 255 374 (27.1) | 10 232 (16.5) | 245 142 (27.9) | <.0001 | |||
| Stage II | 256 524 (27.2) | 12 296 (19.8) | 244 228 (27.7) | ||||
| Stage III | 139 226 (14.8) | 11 052 (17.8) | 128 174 (14.6) | ||||
| Stage IV | 188 956 (20.1%) | 20 736 (33.4%) | 168 220 (19.1%) | ||||
| Stage Unknown | 102 023 (10.8%) | 7687 (12.4%) | 94 336 (10.7%) | ||||
| Initial course of cancer treatment | |||||||
| Chemotherapy | |||||||
| Yes | 312 233 (33.1) | 29 764 (48.0) | 282 469 (32.1) | <.0001 | |||
| No | 607 189 (64.4) | 30 662 (49.5) | 576 527 (65.5) | ||||
| Radiation | |||||||
| Yes | 260 948 (27.7) | 17 946 (28.9) | 243 002 (27.6) | <.0001 | |||
| No | 681 152 (72.3) | 44 057 (71.1) | 634 913 (72.1) | ||||
| Surgery | |||||||
| Yes | 588 227 (62.4) | 34 030 (54.9) | 554 197 (63.0) | <.0001 | |||
| No | 353 882 (37.6) | 27 973 (45.1) | 324 019 (36.8) | ||||
| Comorbidities (≤2 y prior) | |||||||
| NA/no admissions | 603 622 (64.1) | 32 611 (52.6) | 571 011 (64.9) | <.0001 | |||
| 0 comorbidities | 51 381 (5.5) | 3601 (5.8) | 47 780 (5.4) | ||||
| 1-2 comorbidities | 123 754 (13.1) | 10 722 (17.3) | 113 032 (12.8) | ||||
| ≥3 comorbidities | 163 352 (17.3) | 15 069 (24.3) | 148 283 (16.8) | ||||
| . | All . | CAT . | No CAT . | P value . | |||
|---|---|---|---|---|---|---|---|
| Characteristics . | n (%) . | n (%) . | n (%) . | ||||
| All | 942 109 (100.0) | 62 003 (100.0) | 880 106 (100.0) | ||||
| Gender | |||||||
| Male | 443 089 (47.0) | 29 589 (47.7) | 413 500 (47.0) | 0.0003 | |||
| Female | 498 898 (53.0) | 32 402 (52.3) | 466 496 (53.0) | ||||
| Race/Ethnicity | |||||||
| Non-Hispanic White | 573 453 (60.9) | 39 135 (63.1) | 534 318 (60.7) | <.0001 | |||
| African American | 68 336 (7.3) | 6585 (10.6) | 61 751 (7.0) | ||||
| Hispanic | 175 521 (18.6) | 10 780 (17.4) | 164 741 (18.7) | ||||
| Asian/Pacific Islander | 110 895 (11.8) | 4931 (8.0) | 105 964 (12.0) | ||||
| Other/Unknown | 13 904 (1.5) | 572 (0.9) | 13 332 (1.5) | ||||
| Median age at cancer diagnosis (q1, q3) | 65 (56, 75) | 66 (57, 75) | 65 (56, 75) | <.0001 | |||
| Cancer site | |||||||
| Breast | 209 444 (22.2) | 7642 (12.3) | 201 802 (22.9) | <.0001 | |||
| Prostate | 180 807 (19.2) | 7271 (11.7) | 173 536 (19.7) | ||||
| Lung | 135 075 (14.3) | 12 442 (20.1) | 122 633 (13.9) | ||||
| Colorectal | 121 874 (12.9) | 8321 (13.4) | 113 553 (12.9) | ||||
| NHL | 56 771 (6.0) | 3951 (6.4) | 52 820 (6.0) | ||||
| Bladder | 24 964 (2.6) | 2295 (3.7) | 22 669 (2.6) | ||||
| Uterine | 47 295 (5.0) | 3560 (5.7) | 43 735 (5.0) | ||||
| Kidney | 44 345 (4.7) | 2781 (4.5) | 41 564 (4.7) | ||||
| Pancreatic | 36 679 (3.9) | 4604 (7.4) | 32 075 (3.6) | ||||
| Stomach | 24 689 (2.6) | 2162 (3.5) | 22 527 (2.6) | ||||
| Ovarian | 22 528 (2.4) | 2876 (4.6) | 19 652 (2.2) | ||||
| Brain | 19 039 (2.0) | 2249 (3.6) | 16 790 (1.9) | ||||
| Myeloma | 18 599 (2.0) | 1849 (3.0) | 16 750 (1.9) | ||||
| Year of cancer diagnosis | |||||||
| 2005-2007 | 230 451 (24.5) | 16 161 (26.1) | 214 290 (24.3) | <.0001 | |||
| 2008-2010 | 234 624 (24.9) | 16 232 (26.2) | 218 392 (24.8) | ||||
| 2011-2013 | 216 707 (23.0) | 14 301 (23.1) | 202 406 (23.0) | ||||
| 2014-2017 | 260 327 (27.6) | 15 309 (24.7) | 245 018 (27.8) | ||||
| Stage at diagnosis | |||||||
| Stage I | 255 374 (27.1) | 10 232 (16.5) | 245 142 (27.9) | <.0001 | |||
| Stage II | 256 524 (27.2) | 12 296 (19.8) | 244 228 (27.7) | ||||
| Stage III | 139 226 (14.8) | 11 052 (17.8) | 128 174 (14.6) | ||||
| Stage IV | 188 956 (20.1%) | 20 736 (33.4%) | 168 220 (19.1%) | ||||
| Stage Unknown | 102 023 (10.8%) | 7687 (12.4%) | 94 336 (10.7%) | ||||
| Initial course of cancer treatment | |||||||
| Chemotherapy | |||||||
| Yes | 312 233 (33.1) | 29 764 (48.0) | 282 469 (32.1) | <.0001 | |||
| No | 607 189 (64.4) | 30 662 (49.5) | 576 527 (65.5) | ||||
| Radiation | |||||||
| Yes | 260 948 (27.7) | 17 946 (28.9) | 243 002 (27.6) | <.0001 | |||
| No | 681 152 (72.3) | 44 057 (71.1) | 634 913 (72.1) | ||||
| Surgery | |||||||
| Yes | 588 227 (62.4) | 34 030 (54.9) | 554 197 (63.0) | <.0001 | |||
| No | 353 882 (37.6) | 27 973 (45.1) | 324 019 (36.8) | ||||
| Comorbidities (≤2 y prior) | |||||||
| NA/no admissions | 603 622 (64.1) | 32 611 (52.6) | 571 011 (64.9) | <.0001 | |||
| 0 comorbidities | 51 381 (5.5) | 3601 (5.8) | 47 780 (5.4) | ||||
| 1-2 comorbidities | 123 754 (13.1) | 10 722 (17.3) | 113 032 (12.8) | ||||
| ≥3 comorbidities | 163 352 (17.3) | 15 069 (24.3) | 148 283 (16.8) | ||||
Models are stratified by cancer site and adjusted for the competing risk of death using Fine and Gray methodologies.
Models are additionally adjusted for age at cancer diagnosis, stage at cancer diagnosis, initial course of treatment (chemotherapy, radiation, and surgery), neighborhood socioeconomic status, and health insurance at diagnosis or initial treatment. Variables that violated proportional hazard assumption were included as a stratification variable.